Sleep Apnoea Treatment and Healthy Ageing

Key Takeaways

Obstructive sleep apnoea repeatedly narrows or closes the upper airway during sleep, producing arousals and intermittent hypoxaemia that can affect daytime function and cardiovascular physiology. [1]
Continuous positive airway pressure (CPAP) reliably reduces sleepiness in symptomatic adults, including older trial participants, but effects on cognition and broader function are less consistent. [2] [3]
CPAP produces a modest average reduction in blood pressure; responses vary with baseline blood pressure, apnoea severity, and nightly use. [4] [5]
Randomized evidence has not established that prescribing CPAP prevents major cardiovascular events or extends life. Analyses based on achieved adherence are encouraging but are not equivalent to an intention-to-treat treatment effect. [6] [7]

Who This Is Useful For

This page is for readers assessing whether treatment of obstructive sleep apnoea can support healthier ageing. It separates direct treatment effects on breathing and sleepiness from proposed effects on vascular disease, cognition, and survival, for which the certainty and study designs differ. [2] [6] [8]

What Is Being Treated

In obstructive sleep apnoea, recurrent upper-airway obstruction causes continued breathing effort, reduced or absent airflow, oxygen desaturation, and arousal from sleep. These cycles can increase sympathetic activity, disturb vascular regulation, and fragment sleep. The apnoea–hypopnoea index counts breathing events per hour, but oxygen burden, symptoms, sleep stage, body position, and coexisting disease also shape the clinical phenotype. [1]

CPAP uses air pressure to hold the airway open and is the treatment studied most extensively. Oral appliances advance the lower jaw to enlarge or stabilize the airway and can also lower blood pressure modestly on average, although treatment response and tolerability vary. [1] [5]

Evidence at a Glance

Outcome	Main Finding	Interpretation	Main Limitation
Sleepiness and quality of life	Trials in adults aged 70 years and older found reduced subjective sleepiness and improvement in some symptom or quality-of-life domains with CPAP. [2] [3]	Supports a direct symptomatic benefit in older adults with relevant symptoms. [2] [3]	Benefits were not uniform across cognitive, functional, mood, or cardiovascular measures. [2] [3]
Blood pressure	Randomized-trial meta-analyses find average systolic and diastolic reductions of only a few mm Hg. [4] [5]	Supports a small vascular risk-factor effect, with larger responses in some phenotypes. [4]	Mean effects conceal substantial heterogeneity and do not establish fewer clinical events. [4] [6]
Cardiovascular events	SAVE found no reduction in its composite cardiovascular endpoint with CPAP added to usual care. [6]	Does not support a general secondary-prevention claim from CPAP prescription alone. [6]	Participants had established cardiovascular disease, generally little sleepiness, and mean CPAP use of 3.3 hours per night. [6]
Cognition and dementia	Sleep-disordered breathing predicted later cognitive impairment in an older-women cohort, but older-adult CPAP trials have not shown consistent cognitive improvement. [3] [8]	Supports biological and epidemiological relevance, not proof that treatment prevents dementia. [8]	Observational associations are vulnerable to confounding, while trials are often short and underpowered for dementia. [3] [8]

Symptoms and Daily Function in Older Adults

PREDICT randomized 278 adults aged 65 years or older with obstructive sleep apnoea syndrome to CPAP plus best supportive care or supportive care alone. CPAP reduced subjective sleepiness at three and twelve months. Some short-term measures improved, but cognition, mood, functional outcomes, and cardiovascular events did not differ; the trial was not designed to establish effects on lifespan. [2]

A separate three-month trial in 145 adults aged at least 70 with moderate apnoea also found improvement in sleepiness, sleep-related symptoms, and selected quality-of-life domains, without detected benefit for neurocognitive tests or office blood pressure. These results support symptom relief more directly than modification of biological ageing. [3]

Blood Pressure and Vascular Pathways

Recurrent hypoxaemia, arousal, and intrathoracic pressure changes provide plausible links between apnoea and vascular stress. Across 31 randomized trials, CPAP reduced systolic pressure by about 2.6 mm Hg and diastolic pressure by about 2.0 mm Hg compared with inactive treatment, with a larger average nocturnal systolic effect and greater reduction in studies with more frequent breathing events. [1] [4]

A network meta-analysis found similarly modest blood-pressure reductions with CPAP and mandibular advancement devices and no statistically significant difference between them for this outcome. It also found larger reductions with greater nightly CPAP use. This is evidence about a risk factor, not direct evidence that either device extends life. [5]

Cardiovascular Events and Survival

SAVE enrolled 2,717 adults aged 45 to 75 with moderate-to-severe obstructive sleep apnoea and established coronary or cerebrovascular disease. CPAP improved apnoea control, sleepiness, mood, and quality of life, but did not reduce the composite of cardiovascular death, myocardial infarction, stroke, or related hospitalisation over a mean 3.7 years. Average device use was 3.3 hours per night. [6]

An individual-participant-data meta-analysis of SAVE and two other secondary-prevention trials likewise found no intention-to-treat reduction in recurrent major cardiac or cerebrovascular events. An adherence-based analysis associated use of at least four hours per day with lower recurrence risk. Because adherence is not randomly assigned, even methods intended to adjust for time-varying differences cannot exclude all healthy-adherer effects or residual confounding. [7]

The trials therefore do not establish an effect on all-cause mortality or lifespan. They also do not prove that adequate nightly treatment has no cardiovascular effect: limited use, selection of relatively non-sleepy participants, background cardiovascular care, and follow-up duration constrain what these studies can detect. [6] [7]

Cognition and Brain Ageing

In a prospective study of 298 older women without dementia at baseline, sleep-disordered breathing was associated with higher odds of developing mild cognitive impairment or dementia, and measures of hypoxaemia appeared more explanatory than sleep fragmentation or duration. The observational design cannot show that apnoea treatment prevents cognitive decline. [8]

Treatment trials in older adults have measured cognition over months rather than the years commonly required for dementia outcomes and have not shown consistent improvement. A small one-year quasi-experimental study in older adults with mild cognitive impairment reported better cognitive trajectories among CPAP-adherent participants, but non-random adherence and the pilot design limit causal interpretation. [2] [3] [9]

Why Adherence and Phenotype Matter

CPAP acts only while it is worn, so average nightly use changes the delivered treatment exposure. Symptom burden can also influence both motivation to use the device and the likelihood of improvement, while uncontrolled blood pressure and greater apnoea severity may identify groups with more room for a measurable vascular response. These effect modifiers complicate comparisons among efficacy, prescription, and real-world effectiveness. [2] [4] [7]

Evidence Quality and Interpretation

Confidence is high that CPAP controls obstructive breathing events and reduces sleepiness in symptomatic patients, including older adults. Confidence is also high that its average blood-pressure effect is modest, although individual responses vary. [2] [3] [4]

Confidence is lower that CPAP prevents major cardiovascular events. Large secondary-prevention trials have been neutral by intention to treat, while apparent benefit among adherent users comes from analyses that partly lose randomization's protection against confounding. [6] [7]

Confidence is lower still for dementia prevention and life extension. Relevant observational signals exist, but long-duration randomized trials with those outcomes are lacking. Healthy-ageing claims should therefore remain narrower than claims about control of apnoea, sleepiness, and selected intermediate risk factors. [6] [8] [9]

What This Does Not Mean

It does not mean symptom improvement proves that ageing biology has slowed. [2] [3]
It does not mean a neutral cardiovascular trial proves that treatment has no benefit for breathing, sleepiness, mood, or quality of life. [6]
It does not mean an adherence subgroup is equivalent to a randomized comparison of adequate treatment exposure. [7]
It does not mean all people with the same apnoea–hypopnoea index have the same symptoms, hypoxaemic burden, vascular risk, or treatment response. [1] [4]

Practical Interpretation Examples

If CPAP lowers an apnoea–hypopnoea index: this demonstrates physiological control while the device is used, not by itself a reduction in dementia, cardiovascular events, or mortality. [6]
If a study reports a small average blood-pressure change: the mean can include larger, smaller, or absent responses related to baseline pressure, severity, and nightly use. [4] [5]
If adherent users have fewer cardiovascular events: consider both a possible dose-dependent treatment effect and differences between people who can and cannot sustain use. [7]

References

Jordan, A. S., et al. (2014). Adult obstructive sleep apnoea. The Lancet. https://pubmed.ncbi.nlm.nih.gov/23910433/
McMillan, A., et al. (2014). Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. The Lancet Respiratory Medicine. https://pubmed.ncbi.nlm.nih.gov/25172769/
Martínez-García, M. Á., et al. (2019). The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial. European Respiratory Journal. https://pubmed.ncbi.nlm.nih.gov/31164429/
Fava, C., et al. (2014). Effect of CPAP on blood pressure in patients with OSA/hypopnoea: a systematic review and meta-analysis. Chest. https://pubmed.ncbi.nlm.nih.gov/24077181/
Bratton, D. J., et al. (2015). CPAP vs mandibular advancement devices and blood pressure in patients with obstructive sleep apnea: a systematic review and meta-analysis. JAMA. https://pubmed.ncbi.nlm.nih.gov/26624827/
McEvoy, R. D., et al. (2016). CPAP for prevention of cardiovascular events in obstructive sleep apnea. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/27571048/
Sánchez-de-la-Torre, M., et al. (2023). Adherence to CPAP treatment and the risk of recurrent cardiovascular events: a meta-analysis. JAMA. https://pubmed.ncbi.nlm.nih.gov/37787793/
Yaffe, K., et al. (2011). Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. https://pubmed.ncbi.nlm.nih.gov/21828324/
Richards, K. C., et al. (2020). One year of continuous positive airway pressure adherence improves cognition in older adults with mild apnea and mild cognitive impairment. Journal of the American Geriatrics Society. https://pubmed.ncbi.nlm.nih.gov/32108738/

Educational Disclaimer

This page summarizes population and clinical-trial evidence and does not provide a diagnosis, treatment recommendation, or individualized medical advice. Sleep apnoea assessment and treatment depend on symptoms, sleep testing, anatomy, coexisting conditions, treatment tolerance, and clinical context.